Table 1 Demographics and Characteristics of Patients

Age-years

68.5 (47.6–86.3)

72.2 (51.5–88.6)

0.723

Sex (female/male)-%

43.0/57.0

46.8/53.2

0.915

BMI-kg/m²

21.9 (17.5–27.3)

29.6 (24.3–34.7)

0.013

Smoking (Y/N)-%

40.1/59.9

50.9/49.1

0.009

Smoking index-pack/year

33.6 (21.3–45.9)

47.3 (30.6–63.7)

0.001

 Adenocarcinoma

673 (61.7)

109 (63.0)

0.537

 Squamous

269 (24.7)

40 (23.1)

0.941

 SCLC

123 (11.3)

17 (9.80)

0.713

 Others

25 (2.30)

7 (4.10)

0.025

 Stage I

199 (18.3)

3 (1.70)

< 0.001

 Stage II

227 (20.8)

33 (19.1)

0.985

 Stage III

257 (23.6)

44 (25.4)

0.836

 Stage IV

407 (37.3)

93 (53.8)

0.001

 C-PTP(Y/N)-%

45.2/54.8

74.6/25.4

< 0.001

 D-dimer-mg/L

3713 (2336–5369)

1331 (854–1776)

< 0.001

 Platelet- × 10⁹/L

387 (226–543)

252 (157–357)

0.001

 Hemoglobin-g/L

97 (83–114)

109 (91–127)

0.573

 WBC- × 10⁹/L

13.1 (7.62–18.6)

7.73 (4.38–11.1)

0.001

 Chemotherapy(Y/N)-%

65.8/34.2

94.2/5.8

< 0.001

 PS score-point

1.35 (0.66–2.25)

2.31 (1.23–3.47)

0.005

 Metastasis(Y/N)-%

37.3/62.7

53.8/46.2

0.001

 Previous VTE(Y/N)-%

9.9/90.1

17.9/82.1

0.001

 Vascular/lymphatic compression(Y/N)-%

70.1/29.9

90.8/9.2

< 0.001

 Anti-hormonal or anthracycline therapy(Y/N)-%

2.0/98.0

1.7/98.3

0.896

 Time since cancer diagnosis≤6 months(Y/N)-%

49.8/50.2

52.6/47.4

0.916

 CVC(Y/N)-%

3.9/96.1

9.8/90.2

< 0.001

 Cardiovascular risk factors(Y/N)-%

15.0/85.0

29.5/70.5

< 0.001

 Recent hospitalization (Y/N)-%

66.5/33.5

97.7/2.3

< 0.001